RZ-629
/ Rezubio Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 22, 2025
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
(clinicaltrials.gov)
- P1 | N=134 | Recruiting | Sponsor: Rezubio Pharmaceuticals Co., Ltd. | N=50 ➔ 134 | Trial completion date: Jul 2025 ➔ Feb 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2025
Enrollment change • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1